Skip to main content
. Author manuscript; available in PMC: 2016 Jan 7.
Published in final edited form as: Leukemia. 2012 Nov 21;27(6):1437–1440. doi: 10.1038/leu.2012.337

Figure 2.

Figure 2

Supplemental IL-7 and signaling through IGF1R are required for growth in vitro. In vitro growth of xenograft-expanded primary T-ALL cells as measured by resazurin reduction assay. (a), (b) Cells were cultured on MS5-DL1 feeders as in Figure 1, but with WIT-L media lacking the indicated growth factors/cytokines and assayed 4–6 days later. (c) Cells were cultured on MS5-DL1 feeders in WIT-L media as in Figure 1, but with addition of the indicated doses of IGF1R blocking antibody, CP-751,871, and assayed 3 days later. Error bars indicate s.d. of assays performed in triplicate. Statistical significance was calculated in comparison with relevant controls (complete WIT-L media in a; as indicated in b; no CP-751,871 in c). *P<0.05; **P<0.01; ***P<0.001 (Student’s t-test).